TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32091032
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment (control group).
Study: 36245835
Drug: Diclofenac sodium
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac sodium sustained-release tablet (100 mg) once a day for 8 courses (7 days each course)
Study: 34462343
Drug: CC alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC alone
Study: 34462343
Drug: CC with
Normalized name: BD Syringe 5cc with Needle
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC with telemedicine
Study: 34419082
Drug: MitoQ (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: MitoQ (20 mg·day−1)
Study: 39107737
Drug: Titanium implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Titanium implants
Study: 32357900
Drug: Oxymetazoline nasal
Normalized name: oxymetazoline nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxymetazoline nasal spray
Study: 35305347
Drug: Intramuscular 10
Normalized name: Zyprexa IntraMuscular 10mg Powder for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular 10 units (IM group)
Study: 35305347
Drug: Intravenous 10
Normalized name: fat emulsion, intravenous 10% intravenous emulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous 10 units in 100 ml 0.9% NaCl solution over 10-15 min (IV group)
Study: 33982512
Drug: Classic TCM
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Classic TCM prescriptions
Study: 33223020
Drug: Boost SRS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Boost SRS after fractionated radiation therapy
Study: 34374114
Drug: All treatments
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All treatments (MB02, US-bevacizumab, EU-bevacizumab)
Study: 32782254
Drug: Queens choosing
Normalized name: queen palm pollen extract
DrugBank: Syagrus romanzoffiana pollen (DB10482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Queens choosing between two empty nesting chambers; no specific dosage or duration mentioned.
Study: 33506447
Drug: Immunosuppressive agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunosuppressive agents
Study: 36147577
Drug: MET (MET
Approvals — FDA: no, EMA: no, PMDA: no
Description: MET (MET 1000 mg twice daily)
Study: 37264767
Drug: liraglutide 3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: liraglutide 3.0 mg
Study: 33287713
Drug: Standard anti-TB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard anti-TB treatment
Study: 38749259
Drug: Intranasal dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal dexmedetomidine
Study: 32208231
Drug: Exposure and
Normalized name: Anthrax vaccine, adsorbed, pre-exposure and post-exposure prophylaxis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exposure and response prevention (ERP) treatment
Study: 35194648
Drug: Ledipasvir/Sofosbuvir (once-daily)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ledipasvir/Sofosbuvir (once-daily)
Study: 34487346
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatment (Imm)
Study: 34847453
Drug: Nature-based program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nature-based program (2 hours, twice a week for three consecutive weeks)
Study: 32945875
Drug: Combined intervention
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined intervention (motivational enhancement therapy and cognitive behavioral therapy, 6 in-person sessions of 1 hour each and 3 optional group sessions)
Study: 32915099
Drug: L‐DRSEQ‐SRA in
Approvals — FDA: no, EMA: no, PMDA: no
Description: L‐DRSEQ‐SRA in the non‐drinking group
Study: 32915099
Drug: L‐DRSEQ‐SRA
Approvals — FDA: no, EMA: no, PMDA: no
Description: L‐DRSEQ‐SRA
Study: 33560877
Drug: PTR plus
Normalized name: PTR-01
DrugBank: PTR-01 (DB17900)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PTR plus chemotherapy
Study: 36498519
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine (100 micrograms)
Study: 33156201
Drug: Zuspan regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zuspan regimen (4‐g IV loading dose, then a 1‐g/h infusion)
Study: 33156201
Drug: Alternate regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternate regimen (6‐g IV loading dose, then a 2‐g/h infusion)
Study: 34643781
Drug: nCRT (neoadjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: nCRT (neoadjuvant chemoradiation therapy)
Study: 35717156
Drug: Group Interpersonal
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group Interpersonal Psychotherapy (IPT-G) delivered by community health workers (CHWs)
Study: 35717156
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (wait-listed group)
Study: 32924315
Drug: Angong Niuhuang
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angong Niuhuang pill (ANP)
Study: 36892884
Drug: Positive Affect
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Positive Affect Treatment (PAT)
Study: 33872070
Drug: Pembrolizumab (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab (200 mg once every 3 weeks for up to 35 cycles)
Study: 32308204
Drug: Dexamethasone 1
Normalized name: dexamethasone 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 1 mg once daily for 6 months
Study: 35485344
Drug: HBsAg-positive individuals
Normalized name: HBSAG
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HBsAg-positive individuals with HBV-DNA ≥2000 IU/mL
Study: 35485344
Drug: HBsAg-positive individuals
Normalized name: HBSAG
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HBsAg-positive individuals with HBV-DNA <2000 IU/mL
Study: 36322562
Drug: Reduced Nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduced Nicotine Content (RNC) research cigarettes (nicotine content reduced to 0.2 mg over 18 weeks)
Study: 35346577
Drug: Entecavir capsule
Normalized name: Entecavir
DrugBank: Entecavir (DB00442)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Entecavir capsule plus Fuzheng Huayu tablet
Study: 35346577
Drug: Entecavir capsule
Normalized name: Entecavir
DrugBank: Entecavir (DB00442)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Entecavir capsule plus simulant of Fuzheng Huayu
Study: 34270409
Drug: Multidimensional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multidimensional treatment framework (n = 28)
Study: 35094079
Drug: Met injection
DrugBank: Methionine (DB00134)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Met injection (5 g/L Met + 7.5 g/L NaCl)
Study: 33593769
Drug: Dihydroartemisinin/piperaquine (DP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydroartemisinin/piperaquine (DP) treatment
Study: 33472172
Drug: Anserine 500
Normalized name: POTENTILLA ANSERINA WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anserine 500 mg per day
Study: 33518626
Drug: Control measles
Normalized name: MEASLES VIRUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control measles vaccine (n = 85)
Study: 35768985
Drug: ESPB +
Approvals — FDA: no, EMA: no, PMDA: no
Description: ESPB + fentanyl based intravenous patient‐controlled analgesia (IV‐PCA)
Study: 36448621
Drug: Standard BP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard BP lowering treatment
Study: 36448621
Drug: Intensive BP
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive BP lowering treatment
Study: 35989252
Drug: 500-mg MXR
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500-mg MXR tablet manufactured by Merck Pharmaceuticals Manufacturing (Jiangsu) Co.
Study: 35218559
Drug: Terbutaline (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbutaline (4 mg × day−1, n = 13)
Study: 33972742
Drug: sorafenib (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: sorafenib (400 mg twice daily)
Study: 33272309
Drug: Propolis supplementation
Normalized name: propolis
DrugBank: Sodium fluorophosphate (DB09484)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propolis supplementation (300 mg Iranian green propolis extract) three times a day for 2 weeks
Study: 36282537
Drug: risankizumab 150
Normalized name: RISANKIZUMAB 150MG/ML ON-BODY KIT 2.4ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: risankizumab 150 mg (after switching from placebo)
Study: 35404990
Drug: Structured pharmacotherapy
Normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structured pharmacotherapy optimization intervention
Study: 34107509
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (PPDC and HT)
Study: 34613578
Drug: Autologous platelet-rich
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous platelet-rich plasma (PRP) infusion
Study: 38297916
Drug: Exebacase +
Normalized name: Exebacase
DrugBank: Exebacase (DB16161)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exebacase + antibiotics
Study: 38297916
Drug: Antibiotics alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics alone
Study: 32271718
Drug: Antibiotics alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics alone (MRSA patients)
Study: 33993501
Drug: Dupilumab 300
Normalized name: dupilumab 300 MG in 2 ML Auto-Injector
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dupilumab 300 mg every 2 weeks until week 52
Study: 33993501
Drug: Dupilumab 300
Normalized name: dupilumab 300 MG in 2 ML Auto-Injector
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dupilumab 300 mg every 2 weeks until week 24, then 300 mg every 4 weeks until week 52
Study: 33993501
Drug: Placebo (mometasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (mometasone furoate nasal spray) until week 52
Study: 35896277
Drug: Angiotensin-converting enzyme
Normalized name: ACE - Angiotensin-converting enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin-converting enzyme inhibitor-based therapy (a fixed combination of perindopril and indapamide)
Study: 35896277
Drug: Angiotensin-converting enzyme
Normalized name: ACE - Angiotensin-converting enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin-converting enzyme inhibitor-based therapy
Study: 36351735
Drug: Brief pain
Normalized name: Dermoplast Pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brief pain consult (BPC) followed by telehealth physical therapy (PT) in the first 12 weeks (sequenced delivery strategy)
Study: 36351735
Drug: Brief pain
Normalized name: Dermoplast Pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brief pain consult (BPC) followed by telehealth physical therapy (PT) for non-responders (adaptive strategy)
Study: 33174234
Drug: Full-mouth scaling
Normalized name: moth bean extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full-mouth scaling and root planing (SRP) with adjunctive glycine powder air-polishing (GPAP)
Study: 34823018
Drug: Metformin (1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (1,000 mg twice daily)
Study: 38200419
Drug: Antiviral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiviral therapy
Study: 32420649
Drug: Vortioxetine (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vortioxetine (15 mg daily)
Study: 32420649
Drug: Sertraline (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (75 mg daily)
Study: 34223077
Drug: Azithromycin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (2 g, oral dose)
Study: 33492394
Drug: Normal salt
Normalized name: SODIUM CHLORIDE 1 g ORAL TABLET [Normal Salt]
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Normal salt diet (NSD, 6 g NaCl/day)
Study: 34908567
Drug: Tapentadol 50
Normalized name: tapentadol 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tapentadol 50 mg (Group B)
Study: 39427924
Drug: Androgen deprivation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Androgen deprivation therapy (ADT)
Study: 36397446
Drug: LJR ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: LJR ointment
Study: 39197113
Drug: Ubrogepant 100
Normalized name: ubrogepant 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ubrogepant 100 mg
Study: 32573795
Drug: Ubrogepant 100
Normalized name: ubrogepant 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ubrogepant 100 mg plus Sumatriptan 100 mg
Study: 33087441
Drug: Beta Blockers
Normalized name: BETA BLOCKERS/RELATED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta Blockers (BBs)
Study: 32181756
Drug: HD‐MAPs delivering
Approvals — FDA: no, EMA: no, PMDA: no
Description: HD‐MAPs delivering 10 μg HA
Study: 32181756
Drug: HD‐MAPs delivering
Approvals — FDA: no, EMA: no, PMDA: no
Description: HD‐MAPs delivering 15 μg HA
Study: 32181756
Drug: IM injection
Normalized name: filgrastim Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: IM injection of QIV (15 μg/dose)
Study: 34750670
Drug: No drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: No drug (control group)
Study: 35761306
Drug: Psychodynamic Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychodynamic Therapy (PDT)
Study: 32385943
Drug: Calcium hydroxylapatite
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium hydroxylapatite (3.0 mL)
Study: 36043711
Drug: Acetyl-L-carnitine (ALCAR)
Normalized name: acetyl-L-carnitine
DrugBank: Acetylcarnitine (DB08842)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetyl-L-carnitine (ALCAR) 1.5 g BID for 3 months
Study: 35170216
Drug: Rivaroxaban 2.5
Normalized name: rivaroxaban 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban 2.5 mg twice-daily plus aspirin
Study: 35170216
Drug: Placebo on
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo on aspirin background
Study: 34052087
Drug: Injected polyurethane
Normalized name: polyurethane-62
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injected polyurethane foam and gel cushions
Study: 35219973
Drug: Robot-assisted therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Robot-assisted therapy combined with trunk restraint
Study: 33401489
Drug: Integrated depression
Normalized name: Nerve depressants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrated depression treatment and economic strengthening intervention
Study: 32996347
Drug: CLS-FUERTE (multicomponent
Approvals — FDA: no, EMA: no, PMDA: no
Description: CLS-FUERTE (multicomponent behavioral Evidence-Based Treatment)
Study: 32374423
Drug: Monthly injections
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly injections
Study: 34542079
Drug: Cognitive rehabilitation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive rehabilitation therapy (CRT)
Study: 39231780
Drug: Enhanced treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced treatment as usual (ETAU)
Study: 34389292
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg of aspirin per day, initiated from 12 to 20 gestational weeks until 34 weeks of gestation.
Study: 34389292
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg of aspirin per day.
Study: 33440088
Drug: Ad26.COV2.S vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ad26.COV2.S vaccine (5×10^10 viral particles low dose or 1×10^11 viral particles high dose)
Study: 33053570
Drug: Mifepristone (MFP)
DrugBank: Mifepristone (DB00834)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mifepristone (MFP) 50 mg
Study: 33931997
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (standard early enteral nutrition treatment through nasojejunal tube).
Study: 33721623
Drug: Myoinositol 1000
Normalized name: mesoinositol hexanicotinate
DrugBank: Inositol nicotinate (DB08949)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Myoinositol 1000 mg twice daily
Study: 33559255
Drug: Pharmacists maintaining
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacists maintaining adequate antibiotic stock supply
Study: 33559255
Drug: Antibiotics dispensed
Normalized name: Disperse Blue 106
DrugBank: Disperse Blue 106 (DB14203)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics dispensed upon physician recommendation
Study: 32647023
Drug: Preoperative oral
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative oral antibiotics (OA) alone
Study: 33494843
Drug: Association of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Association of Na and K excretion with BMI and age
Study: 34702183
Drug: Wound infiltration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wound infiltration (WI) with a 40 ml bolus of 0.5% Ropivacaine infiltrated at the ports and minimally invasive wound.
Study: 35841422
Drug: LB-102 (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: LB-102 (100 mg QD, 75 mg BID, 100 mg BID)
Study: 34023695
Drug: Facilitated subcutaneous
Normalized name: An adeno-associated virus serotype 9 (AAV9) vector with engineered transgene encoding the human CLN7/MFSD8 gene for expression of active human major facilitator superfamily domain containing 8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Facilitated subcutaneous immunoglobulin therapy (fSCIG)
Study: 33957657
Drug: High-dose oxytocin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose oxytocin (6 milliunits/min)
Study: 33957657
Drug: Standard-dose oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard-dose oxytocin (2 milliunits/min)
Study: 32419540
Drug: Photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic therapy (PDT) alone
Study: 34508116
Drug: BeBo Concept
Approvals — FDA: no, EMA: no, PMDA: no
Description: BeBo Concept exercise program (6-week physical therapy)
Study: 36153027
Drug: Supervised exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supervised exercise therapy (standard treatment, 2 weekly sessions)
Study: 35242595
Drug: Guided internet-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guided internet-based cognitive behavioral therapy (ICBT)
Study: 36340254
Drug: Percutaneous coronary
Normalized name: Glebionis coronaria whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Percutaneous coronary intervention (PCI) with drug-eluting stents
Study: 32592897
Drug: Positive airway
Normalized name: VersaPAP Positive Airway Pressure Device
Approvals — FDA: no, EMA: no, PMDA: no
Description: Positive airway pressure (PAP) therapy during hospitalization, n = 75
Study: 32592897
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group receiving guideline-directed therapy for HF decompensation, n = 75
Study: 35853675
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg IXE every 4 weeks or 2 weeks
Study: 39213738
Drug: Mindfulness-Based Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness-Based Cognitive Therapy (MBCT)
Study: 36282755
Drug: Skin-to-skin contact
Approvals — FDA: no, EMA: no, PMDA: no
Description: Skin-to-skin contact (SSC) for 1 hour daily from birth until postnatal week 5
Study: 34630103
Drug: Metformin 850
Normalized name: metFORMIN 850 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 850 mg twice daily
Study: 39476339
Drug: Once-weekly subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-weekly subcutaneous semaglutide (2.4 mg)
Study: 36150662
Drug: Antibiotic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic treatment for endocarditis
Study: 36209759
Drug: Doxycycline 100
Normalized name: doxycycline 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline 100 mg twice a day for 7 days
Study: 34128838
Drug: Doxycycline 100
Normalized name: doxycycline 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline 100 mg twice a day for 14 days
Study: 34213584
Drug: EcN® 320
Approvals — FDA: no, EMA: no, PMDA: no
Description: EcN® 320 mg, twice daily for 4 weeks and then once daily for 8 weeks (Group B)
Study: 34213584
Drug: Levofloxacin® 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levofloxacin® 500 mg once daily for 4 weeks (Group A)
Study: 34750297
Drug: AHEU (in‐utero
Approvals — FDA: no, EMA: no, PMDA: no
Description: AHEU (in‐utero combination antiretroviral treatment)
Study: 34032758
Drug: Medication safety
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication safety education alone
Study: 37457966
Drug: Inactivated SARS-CoV-2
Normalized name: Inactivated SARS-Cov-2 Vaccine
DrugBank: Inactivated SARS-CoV-2 Vaccine (Chinese Academy of Medical Sciences) (DB15863)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated SARS-CoV-2 vaccine
Study: 38631826
Drug: Aspirin 75
Normalized name: aspirin 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 75 mg daily
Study: 32276883
Drug: Alfaxalone at
Normalized name: alfaxalone
DrugBank: Alfaxalone (DB11371)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfaxalone at 3.5 mg kgâ€“1
Study: 32276883
Drug: Alfaxalone 2
Normalized name: alfaxalone
DrugBank: Alfaxalone (DB11371)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfaxalone 2 mg kgâ€“1 and medetomidine 40 Î¼g kgâ€“1, reversed with atipamezole at 0.16 mg kgâ€“1
Study: 35623880
Drug: High-calcium breakfast
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-calcium breakfast from calcium citrate (∼770 mg/d)
Study: 35623880
Drug: High-calcium breakfast
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-calcium breakfast from skim milk (∼770 mg/d)
Study: 35623880
Drug: Low calcium
Normalized name: Dianeal Low Calcium 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low calcium breakfast (control, ∼70 mg of calcium/d)
Study: 33268715
Drug: Ice cream
Normalized name: Nice Cream 2% Topical Dental Foam (mint)
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ice cream with azithromycin
Study: 34228102
Drug: IV zoledronic
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: IV zoledronic acid (ZA) 0.05 mg/kg
Study: 38940494
Drug: Antiarrhythmic drug
Normalized name: ANTIARRHYTHMICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiarrhythmic drug therapy
Study: 32979708
Drug: Soybean (Soygan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soybean (Soygan 500 mg capsule)
Study: 32979708
Drug: Omega-3 fatty
Normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 fatty acids (Omega-rex 1000 mg soft gel)